Tuberculosis diagnostics market seen hitting $56.4 billion by 2033

Persistence Market Research projects the global tuberculosis diagnostics market will rise from $38 billion in 2026 to $56.4 billion by 2033, driven by early detection efforts, molecular testing adoption and stronger screening programs. The forecast points to steady demand across hospitals and diagnostic labs as governments and health systems expand infectious disease monitoring.

Why it matters: - Tuberculosis remains a major public health threat, so faster and more accurate diagnostics can improve detection, treatment decisions and patient outcomes. - Market growth signals continued spending on early screening, laboratory capacity and infectious disease surveillance. - The forecast also suggests more demand for tests that can identify drug-resistant tuberculosis strains.

What happened: - Persistence Market Research projected the global tuberculosis diagnostics market will reach $56.4 billion by 2033. - The market is estimated at $38 billion in 2026. - The forecast implies a compound annual growth rate of 5.8% from 2026 to 2033. - The report was released June 22, 2026. - Get the sample report.

The details: - The market is being supported by rising healthcare investments, stronger disease surveillance programs and broader use of advanced laboratory testing. - Diagnostic technologies covered in the market include molecular diagnostics, culture-based testing, immunological testing and microscopy. - Molecular diagnostics are gaining attention because they deliver faster and more accurate results. - Molecular testing is especially important for detecting drug-resistant tuberculosis strains. - End users include hospitals, diagnostic laboratories, research institutions and public health organizations. - Hospitals and diagnostic laboratories account for a substantial share of demand because of high testing volumes and access to advanced facilities. - Government-led screening and disease control programs are supporting market expansion. - Growing investments in healthcare infrastructure are creating additional growth opportunities.

Between the lines: - The forecast reflects a shift toward earlier detection and more technologically advanced testing rather than reliance on slower traditional methods. - High costs for advanced diagnostics remain a barrier in low-income regions. - Limited infrastructure, weak laboratory networks and shortages of trained staff can still slow access to testing. - Point-of-care testing is emerging as a key opportunity for market players. - Emerging economies may drive more adoption as healthcare infrastructure expands and public-private partnerships increase.

What's next: - North America is expected to remain a major market because of advanced healthcare infrastructure, strong laboratory networks and investment in infectious disease management. - Asia Pacific is expected to be a key growth region because of its high tuberculosis burden, rising healthcare spending and government prevention programs. - Market participants are likely to focus on faster molecular platforms and more accessible testing models. - Key companies in the market include Abbott Laboratories, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers, QIAGEN N.V., bioMérieux, Hologic Inc., FUJIFILM Holdings Corporation, Thermo Fisher Scientific, Sysmex Corporation, Agilent Technologies, PerkinElmer Inc., Trivitron Healthcare and Molbio Diagnostics. - Request report customization. - Buy the full report.